3Johari V, Loke C. Brief overview of the coagulation cascade [J]. Disease-a-month: DM, 2012, 58(8): 421-423.
4Boudal P, Sommet A, Bagheri H, et al. Bleedings induced by oral anticoagulants: a study of adverse drug reactions reported to Midi-Pyrenees PharmacoVigilance Centre between 2003 and 2006[J]. Therapie, 2010, 65(6): 567-569.
5Walenga JM, Prechel M, Hoppensteadt D, et al. Apixaban as an alternate oral anticoagulant for the management of patients with heparin-induced thrombocytopenia [J]. Clinical and Applied Thrombosis/Hemostasis, 2013, 19(5): 482-487.
6Zhang H, Lowenberg EC, Crosby JR, et al. Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk [J]. Blood, 2010, 116(22): 4684-4692.
7Douketis J, Bell AD, Eikelboom J, et al. Approach to the new oral anticoagulants in family practice: Part 2: addressing frequently asked questions[J]. Can Fam Physician, 2014, 60(11): 997-1001.
8Hohnloser SH. Apixaban: a new direct oral anticoagulant for stroke prevention in atrial fibrillation [J]. European heart journal, 2014, 35 (28): 1828-1829.
